Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.